At the 2017 Keystone Symposia meeting, new research was presented in the fields of innate immunity and type I interferon regulation. Gathering experts from these research communities offered a unique opportunity to discuss new concepts and formulate novel approaches to modulate pathological mechanisms in human inflammatory diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cytogfr.2017.05.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The objective of this study lies in identifying the dominant genotype of C. trachomatis isolated in Republic of Korea (ROK) between 2017 and 2018.
Methods: A total of 504 clinical cervicovaginal swabs from patients were collected and inoculated on McCoy cell monolayers to isolate Chlamydial agents.
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study.
Rheumatol Ther
December 2024
Department of Medicine, University of Toronto, Toronto, ON, Canada.
Introduction: ORAL Surveillance, a post-authorisation safety study of patients with rheumatoid arthritis (RA) enriched for cardiovascular (CV) risk, demonstrated increased risk of major adverse CV events (MACE) and malignancies (excluding non-melanoma skin cancer [NMSC]) for tofacitinib versus tumour necrosis factor inhibitors (TNFi). This analysis of a real-world Canadian observational study evaluated tofacitinib safety/effectiveness in patients meeting or not meeting CV risk criteria.
Methods: CANTORAL included patients with moderate-to-severe RA initiating tofacitinib (10/2017-07/2020; N = 504).
Estimating Socio-Economic Status for Alzheimer's Disease Trials.
J Prev Alzheimers Dis
October 2024
Dorene M Rentz, PsyD, Department of Neurology, Brigham and Women's Hospital, 60 Fenwood Road, 9016S, Boston, MA 02115, USA, Email: Telephone: 617-732-2385, FAX: 617-738-9122.
Introduction: Metrics of a participant's socioeconomic status (SES) are not routinely collected or standardized in clinical trials. This omission limits the ability to evaluate the generalizability of trial results and restricts clinicians from confidently interpreting the efficacy of new treatments across important sub-populations.
Methods: We adapted an SES measure of social disparity; the Hollingshead Two Factor Index of Social Position, which combines education and occupation into a single metric.
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data.
J Prev Alzheimers Dis
July 2024
Gustavo A. Jimenez-Maggiora, Alzheimer's Therapeutic Research Institute, 9860 Mesa Rim Road, San Diego, CA 92121
Background: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies were conducted between 2014 and 2023, with enrollment completed in 2017 and final study results reported in 2023. The study screening process involved the collection of initial clinical, cognitive, neuroimaging, and genetic measures to determine eligibility. Once randomized, enrolled participants were assessed every four weeks over a 4.
View Article and Find Full Text PDFMosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Infect Dis
November 2024
Janssen Research & Development, Titusville, NJ, USA.
Background: HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective efficacy against HIV-1 acquisition. Although pre-exposure prophylaxis in groups with high vulnerability can be very effective, barriers to its use, such as perceived low acquisition risk, fear of stigma, and concerns about side-effects, remain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!